Golimumab performs well in new evidence review

Share Button

Golimumab, rheumatoid arthritis drug, psoriatic arthritis drug, arthritis digestGolimumab, a tumor necrosis factor inhibitor that is used for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has been found to work well and offers a good safety profile, a team outlines in Therapeutic Advances in Musculoskeletal Disease.

The experts looked at data from 12 trials that evaluated golimumab in inflammatory arthritis and the results bode well:

“Golimumab was found to be clinically effective and also have a good safety profile in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis based on data available from large studies.”

Click here to read the original research.

Arthritis Digest Magazine was selected by Feedspot as one of the Top 5 Arthritis Blogs on the internet in 2018.

For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.

“Amazing magazine and the first I’ve read from beginning to end.” Mrs E Crowther, Dorset

“There’s so much news and information to digest, and it’s all calorie free. Brilliant!” A Alexander, Glasgow
“As we are all living longer, it gives us hope for a future with less pain. Arthritis Digest gives us information on the up to date treatments.”Mrs Healey, Devon
“Full of interesting information and tips.” Mr G Thurlow, East Yorkshire

Google+ | Privacy Policy | FTC Disclaimer

Copyright © 2013. All Rights Reserved.